Blog: Technologies
Protected: Biotech Valuation
Password Protected
To view this protected post, enter the password below:
The Top 100 VCs in US biotechs
Where the money is: The top 100(+) VCs investing in U.S. biotechs Warning: Read this before looking at the sortable list below. (No, I mean it. Stop.) Bioregnum by John Carroll 2015 proved to be the biggest year on record for venture investing in U.S. biotechs. A...
Dietary Supplement Greatly Extends Worm Life Span
Drug seems to mimic the biological effects of calorie restriction, letting worms live up to 70 percent longer. By Virginia Hughes, for National Geographic PUBLISHED MAY 14, 2014 A light micrograph of Caenorhabditis elegans, a soil-dwelling nematode often used in...
Alpha-Ketoglutarate: Physiological Functions and Applications
Alpha-Ketoglutarate: Physiological Functions and ApplicationsNan Wu, Mingyao Yang, Uma Gaur, Huailiang Xu, Yongfang Yao, and Diyan Li* Alpha-ketoglutarate (AKG) is a key molecule in the Krebs cycle determining the overall rate of the citric acid cycle of...
Targets for future drugs of AD
The hope for future drugs Currently, there are five FDA-approved Alzheimer's drugs that treat the symptoms of Alzheimer's — temporarily helping memory and thinking problems — with a sixth drug available globally. But these medications do not treat the underlying...
HUP on memory in AD
Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Abstract AIM: To evaluate the efficacy and safety of tablet huperzine-A (Hup) in patients with Alzheimer's disease. METHODS: Using multicenter, prospective, double-blind,...
Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer’s Disease
ORIGINAL ARTICLE A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease Mary Sano, Ph.D., Christopher Ernesto, M.S., Ronald G. Thomas, Ph.D., Melville R. Klauber, Ph.D., Kimberly Schafer, M.S., Michael Grundman, M.D., M.P.H.,...
Neurotrope – Alzheimer’s trial Phase 2
Neurotrope misses primary endpoint in Alzheimer’s trial by Nick Paul Taylor | May 1, 2017 6:59am A phase 2 trial of Neurotrope’s Alzheimer’s disease candidate has missed its primary endpoint. The study set out to show bryostatin improved performance on a...
U.S. med tech venture investment wanes
U.S. med tech venture investment wanes--even as venture-backed M&A holds strong by Stacy Lawrence | Jan 11, 2016 12:00pm Venture capital investment in the U.S. jumped to $59 billion last year--almost twice what it was a scant 5 years ago, according to the latest...
The Most Active VCs In Medical Devices
The Most Active VCs In Medical Devices and Their Investments In One Infographic NEA, Versant Ventures, and High-Tech Grunderfonds are the three most active investors in medical device startups. Funding to medical device startups is on track to pick back up this...
